Within the 3 cancer types (ovarian cancer, esophageal cancer and lung adenocarcinoma) that were commonly mutated in BRD9 and ACTL6A, a significant comutation relationship (p<0.001, log odds ratio = 1.051) was also shown in BRD9 and ACTL6A (Fig 7), which suggested that they may drive the oncogenic process together by affecting the same pathways. The gene discussed is BRD9; the disease is ovarian cancer.